Trichofolliculoma is a benign skin tumor which is typically found on the face, scalp, and neck. It is a common skin condition that affects both men and women, although it is more commonly seen in women. Trichofolliculoma is characterized by a single, firm, dome-shaped bump with a central pore from which hairs emerge. It is usually painless and is not associated with any other medical conditions. In this article, we will take a closer look at the causes and treatment options for trichofolliculoma.
Trichofolliculoma is a benign skin tumor which is typically found on the face, scalp, and neck. It is a common skin condition that affects both men and women, although it is more commonly seen in women. Trichofolliculoma is characterized by a single, firm, dome-shaped bump with a central pore from which hairs emerge. It is usually painless and is not associated with any other medical conditions.
The exact cause of trichofolliculoma is unknown, but it is believed to be related to an abnormal hair follicle. The abnormal hair follicle is thought to be caused by a combination of genetic and environmental factors. It is believed that the abnormal hair follicle is caused by a mutation in the gene that controls the growth and development of hair follicles. This mutation causes the hair follicle to become enlarged and develop a central pore from which hairs emerge.
Trichofolliculoma is typically diagnosed by a physical exam. The doctor will examine the skin for the characteristic dome-shaped bump with a central pore from which hairs emerge. The doctor may also order additional tests such as a biopsy to confirm the diagnosis.
The treatment for trichofolliculoma typically involves surgical removal of the tumor. The procedure is usually done under local anesthesia and is usually successful in removing the entire tumor. In some cases, the tumor may recur and require additional surgery. In some cases, the doctor may recommend a topical cream or ointment to reduce the size of the tumor. These creams and ointments typically contain retinoids or corticosteroids, which are medications that can reduce inflammation and shrink the tumor. In rare cases, the doctor may recommend radiation therapy to shrink the tumor. This is usually done if the tumor is large or if it is not responding to other treatments.
Trichofolliculoma is a benign skin tumor which is typically found on the face, scalp, and neck. It is a common skin condition that affects both men and women, although it is more commonly seen in women. The exact cause of trichofolliculoma is unknown, but it is believed to be related to an abnormal hair follicle. Trichofolliculoma is typically diagnosed by a physical exam and is usually treated with surgical removal of the tumor. In some cases, topical creams or ointments may be used to reduce the size of the tumor or radiation therapy may be recommended.
1.
NEJM: Fluorescent guide can aid in the detection of tumors that are still present after breast cancer surgery.
2.
In a randomized trial, the kinder, gentler regimen for classical Hodgkin wins out.
3.
FDA Expands Durvalumab Label to Operable Lung Cancer
4.
New guidelines expand access to lung cancer screening, but gaps remain in reaching rural and uninsured populations
5.
There is a 40% reduction in the risk of 9 cancers with good cardiorespiratory fitness.
1.
The Architect's Dilemma: Remodeling the Tumor Microenvironment for a New Era of Cancer Immunotherapy
2.
Harnessing Artificial Intelligence in Oncology: Innovations in Diagnosis, Treatment, and Patient Care
3.
Unveiling the Hidden Benefits of Lymphedema Treatment
4.
IGF2BP1 in Blood Disorders: Therapeutic Potential and Comprehensive Functional Insights
5.
Florinef: Understanding Its Uses and Side Effects
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part II
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
3.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
4.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
5.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation